Gabather AB (publ) (FRA:5J2)
Germany · Delayed Price · Currency is EUR 0.0002
0.00 (0.00%)
At close: Dec 1, 2025
Gabather AB Company Description
Gabather AB (publ), a pharmaceutical company, develops drug candidates for the treatment of central nervous system diseases.
The company offers drugs primarily in the areas of anti-psychotics, anti-depressants and anxiolytics, and analgesics, as well as cognition-enhancing treatments, including Alzheimer’s disease.
It focuses on developing GT-002, a pro-cognitive drug candidate for the treatment of Alzheimer’s disease, schizophrenia, and major depressive disorders.
The company was incorporated in 2014 and is based in Södertälje, Sweden.
Gabather AB (publ)
| Country | Sweden |
| Founded | 2014 |
| Industry | Pharmaceutical Preparations |
| Employees | 3 |
| CEO | Michael-Robin Witt |
Contact Details
Address: Forskargatan 20J Södertälje, 151 36 Sweden | |
| Phone | 46 7 36 87 28 39 |
| Website | gabather.com |
Stock Details
| Ticker Symbol | 5J2 |
| Exchange | Frankfurt Stock Exchange |
| Fiscal Year | January - December |
| Reporting Currency | SEK |
| SIC Code | 2834 |
Key Executives
| Name | Position |
|---|---|
| Michael-Robin Witt | Chief Executive Officer |
| Christine Ryan | Chief Operating Officer |